SERB Pharmaceuticals, a global specialty pharmaceutical company focused on rare diseases and medical emergencies, announced that ThyroSafe potassium iodide tablets are now commercially available in a 130 mg dose.

Boston, 12 January 2026: SERB Pharmaceuticals, a global speciality pharmaceutical company focused on rare diseases and medical emergencies, has appointed Dr Peter C. Adamson, MD, FASCO, to its US Board as a Non-Executive Director. Dr. Adamson being exceptional credentials as a globally recognized physician-scientist and leader in oncology drug development and clinical pharmacology. Dr Adamson […]

London, 17 November 2025: SERB Pharmaceuticals is pleased to announce the appointment of Dr. Vignesh Rajah as its Chief Medical Officer (CMO). Dr. Rajah brings over two decades of global experience leading medical and clinical organisations in US and European pharmaceutical and biotech companies. This strategic appointment marks a significant milestone in SERB’s growth journey. […]